 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
16 May 2000 | Volume 132 Issue 10 | Pages 769-779
Background: The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) recommends treatment guidelines based on cholesterol level and number of risk factors.
Objective: To evaluate how the cost-effectiveness ratios of cholesterol-lowering therapies vary according to different risk factors.
Design: Cost-effectiveness analysis.
Data Sources: Published data.
Target Population: Women and men 35 to 84 years of age with low-density lipoprotein cholesterol levels of 4.1 mmol/L or greater (
Time Horizon: 30 years.
Perspective: Societal.
Interventions: Step I diet, statin therapy, and no preventive treatment for primary and secondary prevention.
Outcome Measures: Incremental cost-effectiveness ratios.
Results of Base-Case Analysis: Incremental cost-effectiveness ratios for primary prevention with step I diet ranged from $1900 per quality-adjusted life-year (QALY) gained to $500 000 per QALY depending on risk subgroup characteristics. Primary prevention with a statin compared with diet therapy was $54 000 per QALY to $1 400 000 per QALY. Secondary prevention with a statin cost less than $50 000 per QALY for all risk subgroups.
Results of Sensitivity Analysis: The inclusion of niacin as a primary prevention option resulted in much less favorable incremental cost-effectiveness ratios for primary prevention with a statin (>$500 000 per QALY).
Conclusions: Cost-effectiveness of treatment strategies varies significantly when adjusted for age, sex, and the presence or absence of additional risk factors. Primary prevention with a step I diet seems to be cost-effective for most risk subgroups but may not be cost-effective for otherwise healthy young women. Primary prevention with a statin may not be cost-effective for younger men and women with few risk factors, given the option of secondary prevention and of primary prevention in older age ranges. Secondary prevention with a statin seems to be cost-effective for all risk subgroups and is cost-saving in some high-risk subgroups.
Author and Article Information
From Harvard School of Public Health, Boston, Massachusetts; University of Alabama at Birmingham, Birmingham, Alabama; Erasmus University Medical School, Rotterdam, the Netherlands; and University of California, San Francisco, School of Medicine, San Francisco, California.
Disclosure: The Harvard Program on the Economic Evaluation of Medical Technology has received funding from Merck (unrestricted funds, unrelated to cholesterol-lowering drugs). Drs. Weinstein and Goldman were co-investigators for the economic substudy of the CARE study of pravastatin funded by Bristol-Myers Squibb.
Grant Support: By grant R01 HS 06258 from the Agency for Healthcare Research and Quality, unrestricted funds from the Harvard Program on the Economic Evaluation of Medical Technology (Ms. Prosser), National Library of Medicine Training Grant 5T15LM07092-08 (Ms. Prosser), and a Faculty Development Award in Pharmacoeconomics from the Pharmaceutical Research and Manufacturers of America Foundation (Dr. Stinnett).
Requests for Single Reprints: Milton C. Weinstein, PhD, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115-5924.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Ms. Prosser: Department of Ambulatory Care and Prevention, Harvard Medical School, 126 Brookline Avenue, Boston, MA 02215.
Dr. Stinnett: University of Alabama at Birmingham, 330 RPHB, Birmingham, AL 35294-0022.
Ms. Goldman, Mr. Williams, and Dr. Weinstein: Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115-5924.
Dr. Hunink: Erasmus Medical Center, Box 1738, 3000 DR Rotterdam, the Netherlands.
Dr. Goldman: Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143.
Author Contributions: Conception and design: L. Prosser, A.A. Stinnett, M.C. Weinstein.
Analysis and interpretation of the data: L. Prosser, P.A. Goldman, M.C. Weinstein.
Drafting of the article: L. Prosser.
Critical revision of the article for important intellectual content: P.A. Goldman, M.G.M. Hunink, L. Goldman, M.C. Weinstein.
Final approval of the article: L. Prosser, A.A. Stinnett, P.A. Goldman, L.W. Williams, M.G.M. Hunink, L. Goldman, M.C. Weinstein.
Obtaining of funding: M.C. Weinstein.
Administrative, technical, or logistic support: P.A. Goldman, L.W. Williams.
Collection and assembly of data: L. Prosser, P.A. Goldman. ARTICLE
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
160 mg/dL), divided into 240 risk subgroups according to age, sex, and the presence or absence of four coronary heart disease risk factors (smoking status, blood pressure, low-density lipoprotein cholesterol level, and high-density lipoprotein cholesterol level).
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. J. Steiner, W. D. Brown, and E. Liles An Assessment of the New Lipid Screening Guidelines Pediatrics, October 1, 2008; 122(4): 904 - 905. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Gill and Yingxia Chen Quality of Lipid Management in Outpatient Care: A National Study Using Electronic Health Records American Journal of Medical Quality, September 1, 2008; 23(5): 375 - 381. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Nexoe, P. A. Halvorsen, and I. S. Kristiansen Review Article: Critiques of the risk concept -- valid or not? Scand J Public Health, December 1, 2007; 35(6): 648 - 654. [Abstract] [PDF]
|
|
|
|
 |
|
 P. S. Chan, B. K. Nallamothu, H. S. Gurm, R. A. Hayward, and S. Vijan Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease Circulation, May 8, 2007; 115(18): 2398 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fidan, B. Unal, J. Critchley, and S. Capewell Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010 QJM, May 1, 2007; 100(5): 277 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Rodondi, P. Yerly, A. Gabriel, W. F. Riesen, M. Burnier, F. Paccaud, and P. Bovet Microalbuminuria, but not cystatin C, is associated with carotid atherosclerosis in middle-aged adults Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1107 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. H Franco, E. W Steyerberg, A. Peeters, and L. Bonneux Effectiveness calculation in economic analysis: the case of statins for cardiovascular disease prevention. J. Epidemiol. Community Health, October 1, 2006; 60(10): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Chelmowski Cost-effectiveness of statins added to aspirin therapy. Ann Intern Med, August 1, 2006; 145(3): 233 - 233. [Full Text] [PDF]
|
|
|
|
|
|
M. Pignone Cost-Effectiveness of Statins Added to Aspirin Therapy. Ann Intern Med, August 1, 2006; 145(3): 233 - 234. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dalziel, L. Segal, and M. de Lorgeril A Mediterranean Diet Is Cost-Effective in Patients with Previous Myocardial Infarction J. Nutr., July 1, 2006; 136(7): 1879 - 1885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zwanziger, W. J. Hall, A. W. Dick, H. Zhao, A. I. Mushlin, R. M. Hahn, H. Wang, M. L. Andrews, C. Mooney, H. Wang, et al. The Cost Effectiveness of Implantable Cardioverter-Defibrillators: Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2310 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Cornuz, A Gilbert, C Pinget, P McDonald, K Slama, E Salto, and F Paccaud Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison Tob. Control, June 1, 2006; 15(3): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. T. Ayas, J. M. FitzGerald, J. A. Fleetham, D. P. White, M. Schulzer, C. F. Ryan, R. Ghaeli, G. W. Mercer, P. Cooper, M. C. Y. Tan, et al. Cost-effectiveness of Continuous Positive Airway Pressure Therapy for Moderate to Severe Obstructive Sleep Apnea/Hypopnea. Arch Intern Med, May 8, 2006; 166(9): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Hall Religious Attendance: More Cost-Effective Than Lipitor? J Am Board Fam Med, March 1, 2006; 19(2): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Clouse, J. Chen, H. M. Krumholz, M. E. Clouse, J. Chen, and H. M. Krumholz Noninvasive Screening for Coronary Artery Disease With Computed Tomography Is Useful Circulation, January 3, 2006; 113(1): 125 - 146. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Katon, M. Schoenbaum, M.-Y. Fan, C. M. Callahan, J. Williams Jr, E. Hunkeler, L. Harpole, X.-H. A. Zhou, C. Langston, J. Unutzer, et al. Cost-effectiveness of Improving Primary Care Treatment of Late-Life Depression Arch Gen Psychiatry, December 1, 2005; 62(12): 1313 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. H Franco, A. Peeters, C. W N Looman, and L. Bonneux Cost effectiveness of statins in coronary heart disease J. Epidemiol. Community Health, November 1, 2005; 59(11): 927 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Smith and R. L. Keeney Your Money or Your Life: A Prescriptive Model for Health, Safety, and Consumption Decisions Management Science, September 1, 2005; 51(9): 1309 - 1325. [Abstract] [PDF]
|
|
|
|
|
|
H.T. Ong The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient QJM, August 1, 2005; 98(8): 599 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Beinfeld, E. Wittenberg, and G. S. Gazelle Cost-effectiveness of Whole-Body CT Screening Radiology, February 1, 2005; 234(2): 415 - 422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Pletcher, J. A. Tice, M. Pignone, and W. S. Browner Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis Arch Intern Med, June 28, 2004; 164(12): 1285 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Aronow, G. M. Novaro, M. S. Lauer, D. M. Brennan, A. M. Lincoff, E. J. Topol, D. J. Kereiakes, and S. E. Nissen In-Hospital Initiation of Lipid-Lowering Therapy After Coronary Intervention as a Predictor of Long-term Utilization: A Propensity Analysis Arch Intern Med, November 24, 2003; 163(21): 2576 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
B. R. Schackman, K. A. Freedberg, M. C. Weinstein, P. E. Sax, E. Losina, H. Zhang, and S. J. Goldie Cost-effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults Arch Intern Med, November 25, 2002; 162(21): 2478 - 2486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Krumholz, W. S. Weintraub, W. D. Bradford, P. A. Heidenreich, D. B. Mark, and A. D. Paltiel Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it? J. Am. Coll. Cardiol., August 21, 2002; 40(4): 603 - 615. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Mark and M. A. Hlatky Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II Circulation, July 30, 2002; 106(5): 626 - 630. [Full Text] [PDF]
|
|
|
|
|
|
L. Wartofsky Update in Endocrinology Ann Intern Med, October 16, 2001; 135(8_Part_1): 601 - 609. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Federman, A. S. Adams, D. Ross-Degnan, S. B. Soumerai, and J. Z. Ayanian Supplemental Insurance and Use of Effective Cardiovascular Drugs Among Elderly Medicare Beneficiaries With Coronary Heart Disease JAMA, October 10, 2001; 286(14): 1732 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Greenland, S. C. Smith Jr, and S. M. Grundy Improving Coronary Heart Disease Risk Assessment in Asymptomatic People: Role of Traditional Risk Factors and Noninvasive Cardiovascular Tests Circulation, October 9, 2001; 104(15): 1863 - 1867. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Clark Jr Cost-Effectiveness Analyses Ann Intern Med, September 4, 2001; 135(5): 382 - 382. [Full Text] [PDF]
|
|
|
|
|
|
J. Beaird Using Cost-Effectiveness To Target Cholesterol Reduction Ann Intern Med, August 21, 2001; 135(4): 299 - 300. [Full Text] [PDF]
|
|
|
|
 |
|
 S. B Hulley, D. Grady, and W. S Browner Statins: underused by those who would benefit BMJ, October 21, 2000; 321(7267): 971 - 972. [Full Text]
|
|
|
|
 |
|
 Cost-Effectiveness of Cholesterol Reduction Journal Watch Cardiology, August 4, 2000; 2000(804): 9 - 9. [Full Text]
|
|
|
|
 |
|
 Do All Populations Benefit from Statin Drugs? Journal Watch Women's Health, July 26, 2000; 2000(726): 1 - 1. [Full Text]
|
|
|
|
 |
|
 Cost-Effectiveness of Cholesterol Lowering Varies Widely Journal Watch (General), June 16, 2000; 2000(616): 3 - 3. [Full Text]
|
|
|
|
|
|
A. M. Garber Using Cost-Effectiveness Analysis To Target Cholesterol Reduction Ann Intern Med, May 16, 2000; 132(10): 833 - 835. [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Waldmann, R. Levy, and B. S. Coller Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy Hematology, January 1, 2000; 2000(1): 394 - 408. [Abstract] [Full Text] [PDF]
|
|
Article
